trending Market Intelligence /marketintelligence/en/news-insights/trending/5kgZN_jt053GJLyfgaP_Fw2 content esgSubNav
In This List

Atara Biotherapeutics CEO to step down

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Atara Biotherapeutics CEO to step down

Atara Biotherapeutics Inc. said Isaac Ciechanover has decided to step down as president and CEO.

Ciechanover will keep serving at Atara Biotherapeutics until June 30 or until the appointment of a replacement. He became president and CEO of Atara Biotherapeutics in August 2012.

The company's board has formed a search committee to evaluate candidates for the CEO position.

Atara develops cancer treatments. Its most advanced T cell immunotherapy, tab-cel, is being studied for treating patients with Epstein-Barr virus associated with a post-transplant lymphoproliferative disorder as well as other EBV-associated hematologic and solid tumors, including nasopharyngeal carcinoma.